Who makes Autoantibody Reductive Therapy?

Autoantibody Reductive Therapy is developed by University of Alabama at Birmingham.

What development phase is Autoantibody Reductive Therapy in?

Autoantibody Reductive Therapy is in Phase 2.

What are the side effects of Autoantibody Reductive Therapy?

Common side effects include Leukocytosis, Rash, Weakness, Hypotension.

Last reviewed 2026-04-20 · How we verify

Autoantibody Reductive Therapy

University of Alabama at Birmingham · Phase 2 active Small molecule Quality 5/100

At a glance

Generic name	Autoantibody Reductive Therapy
Sponsor	University of Alabama at Birmingham
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

Leukocytosis
Rash
Weakness
Hypotension

Key clinical trials

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Autoantibody Reductive Therapy CI brief — competitive landscape report
Autoantibody Reductive Therapy updates RSS · CI watch RSS
University of Alabama at Birmingham portfolio CI